Cancer Therapy Advisor

Cancer Therapy Advisor
Treatment Sequence Impacts Survival in BRAF-Mutant Metastatic Melanoma

Treatment sequence can impact survival in patients with BRAF V600-mutant metastatic melanoma, according to results from the phase 3 DREAMseq trial.

Cancer Therapy Advisor
Neoadjuvant Regimens Best Standard Care in HER2+ Breast Cancer

Two neoadjuvant treatment regimens can improve pCR rates over standard care in patients with HER2-positive breast cancer, according to phase 2 results published in Nature Communications.

Cancer Therapy Advisor
Men and Women Differ in Their Refusal of Breast Cancer Treatments

Women with breast cancer are more likely than their male counterparts to refuse hormone therapy or surgery, according to a retrospective study published in Clinical Breast Cancer.

Cancer Therapy Advisor
Brentuximab Vedotin Plus CHP Provides Lasting Benefit in Peripheral T-Cell Lymphoma

The survival benefits seen with brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone persist at 5 years, according to updated results from the ECHELON-2 trial.

Cancer Therapy Advisor
Digital Symptom Monitoring Can Improve Outcomes of Cancer Care

Digital symptom monitoring using patient-reported outcome surveys can improve clinical outcomes in patients with cancer, according to new research. 

Cancer Therapy Advisor
Breakthrough COVID-19 May Be More Common in Patients With Lymphoid Malignancies

Patients with lymphoproliferative cancers may have a higher risk of breakthrough COVID-19 than patients with myeloproliferative cancers, according to research published in Blood.

Cancer Therapy Advisor
Can Quality of Life Assessments Predict PFS, OS Across Cancer Types?

Studies have suggested that quality of life assessments can predict PFS and OS in patients with cancer, though this doesn’t appear to hold true for all cancer types or in all treatment settings. 

Cancer Therapy Advisor
Enasidenib Improves Responses in IDH2-Mutant Acute Myeloid Leukemia

Adding enasidenib to azacitidine significantly improved responses in older patients with newly diagnosed, IDH2-mutant AML, according to research published in The Lancet Oncology.

Cancer Therapy Advisor
Maintenance Olaparib Provides Long-Term PFS Benefit in Ovarian Cancer

The PFS benefit observed with olaparib maintenance persists after treatment completion in patients with advanced ovarian cancer, according to research published in The Lancet Oncology.

Cancer Therapy Advisor
Organ Transplant Recipients at Risk of Multiple Skin Cancers

Organ transplant recipients may be at risk of developing multiple skin cancers, according to a study published in JAMA Dermatology.

Cancer Therapy Advisor
Subscribe to Cancer Therapy Advisor

source list reference

rgb(171, 222, 222)
rgb(219, 18, 118)
200, 66, 245
rgb(195, 2, 230)
rgb (247, 7, 79)
rgb(14, 133, 237)
rgb(252, 3, 223)
rgb(209, 15, 15)
rgb(115, 43, 196)
rgb(9, 151, 227)
rgb(252, 186, 3)
rgb(242, 0, 137)
rgb (247, 7, 79)
rgb(48, 38, 189)
rgb(231, 165, 240)
rgb(230, 21, 49)
rgb (252, 186, 3)
rgb(156, 242, 7)
rgb(91, 128, 189)
rgb(247, 139, 109)
rgb(224, 4, 129)
rgb(20, 13, 222)
rgb(84, 54, 94)
rgb(80, 147, 199)
rgb(117, 2, 247)
rgb(153, 146, 129)
rgb (245, 152, 2)
rgb(169, 196, 201)
rgb(5, 235, 235)
rgb(235, 190, 9)
rgb(209, 227, 11)
200, 66, 245
rgb (191, 171, 145)
rgb(126, 14, 237)
rbg(167, 124, 235)
rgb (132, 101, 173)
rbg(16, 162, 230)
rgb(217, 7, 192)
rgb(224, 224, 4)
rgb(2, 230, 230)
rgb(235, 64, 52)